Home > Search Clinical Trials > Cancer - Lung

IRB No. O25-227-1 (Dr. Nathaniel Robinson, PI): A Phase 2, randomized, open-label, active-controlled study of JNJ-90301900 in combination with chemoradiation followed by durvalumab in locally advanced and unresectable Stage III non-small cell lung cancer

The purpose of this study is to see how effective the injection of the radiation enhancer called JNJ-90301900 into tumor(s), before receiving concurrent chemoradiotherapy (cCRT) followed by immunotherapy (cIT) is, compared to receiving cCRT alone followed by cIT (without JNJ-90301900).

IRB No. U26-053-2 (Dr. Nathaniel Robinson, PI): A Phase III, Randomized, Double-Blind, Multicenter; Global Study of Rilvegostomig or Pembrolizumab Monotherapy for the First-line Treatment of Patients with PD-L1-high Metastatic Non-small cell Lung Cancer (ARTEMIDE-Lung04)

The purpose of this study is to learn more about the effectiveness and safety of the study drug rilvegostomig (also called AZD2936) compared to pembrolizumab (also called KEYTRUDA), a standard treatment option for metastatic NSCLC.